The Chronic Refractory Gout market report also offers comprehensive insights into the Chronic Refractory Gout market size, share, Chronic Refractory Gout epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Refractory Gout market size growth forward.
Some of the key highlights from the Chronic Refractory Gout Market Insights Report:
Several key pharmaceutical companies, including Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others, are developing novel products to improve the Chronic Refractory Gout treatment outlook.
In March 2023, the Phase 3 DISSOLVE I and II studies demonstrated that SEL-212 achieved response rates of 56% and 47%, respectively, in patients receiving monthly doses of 0.15 mg/kg. Notably, 75% of participants in the DISSOLVE I extension phase maintained their response through 12 months without infusion reactions or new safety concerns. These results highlight SEL-212’s potential as an effective treatment for CRG.
In August 2024, the FDA granted Fast Track designation to AR882, a novel URAT1 inhibitor, for treating clinically visible tophaceous gout. This designation aims to expedite the development and review process, reflecting the unmet medical needs in this patient population.
The Chronic Refractory Gout (CRG) market was valued at approximately USD 1,393 million across the 7MM in 2023. Market expansion is anticipated with the introduction of emerging therapies during the 2024–2034 forecast period.
Among the 7MM, the United States held the largest market share, accounting for around USD 1,221 million in 2023, with expectations of further growth by 2034. The prevalence of CRG was also highest in the U.S., with nearly 201,000 cases in 2023, a figure projected to rise by 2034.
Market growth is driven by rising gout prevalence, advancements in therapy, and increased awareness. However, challenges such as high treatment costs, limited specialist availability, and regulatory hurdles slow progress. Access to biologics is also impacted by varying reimbursement policies. Key unmet needs include more effective and affordable treatments, along with improved access to specialist care.
In Japan, the CRG market was valued at USD 40 million in 2023 and is expected to grow at a CAGR of 9.1% by 2034.
A significant regulatory milestone occurred in August 2024, when AR882 received FDA fast-track designation for gout, accelerating its development process.
As per DelveInsight analysis, the Chronic Refractory Gout market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Chronic Refractory Gout Market Landscape
Chronic Refractory Gout Overview
Chronic Refractory Gout is an advanced and persistent form of gout that remains unresponsive to standard treatments. Gout, a type of inflammatory arthritis, occurs due to the buildup of uric acid crystals in the joints, causing sudden bouts of pain and swelling. In its refractory state, the condition continues despite intensive treatment efforts, leading to persistent symptoms and an increased risk of joint damage.
Do you know the treatment paradigms for different countries? Download our Chronic Refractory Gout Market Sample Report
Chronic Refractory Gout Epidemiology Insights
In 2023, the United States had the highest number of diagnosed prevalent cases of Chronic Refractory Gout, totaling 201,000. This number is expected to increase in the coming years.
Chronic Refractory Gout Epidemiology Segmentation
DelveInsight’s Chronic Refractory Gout market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Refractory Gout historical patient pools and forecasted Chronic Refractory Gout patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Refractory Gout Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Chronic Refractory Gout Prevalence
Age-Specific Chronic Refractory Gout Prevalence
Gender-Specific Chronic Refractory Gout Prevalence
Diagnosed and Treatable Cases of Chronic Refractory Gout
Visit for more @ Chronic Refractory Gout Epidemiological Insights
Chronic Refractory Gout Treatment Market
The management of CRG includes both short-term and long-term approaches. For acute treatment, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are commonly used to relieve pain and inflammation, while colchicine can effectively treat gout attacks, though it may cause gastrointestinal discomfort. Corticosteroids, administered orally or through injections, are also effective in controlling severe inflammation.
Chronic management focuses on preventing future complications. Urate-lowering therapies like allopurinol or febuxostat help reduce uric acid levels, with alternatives such as pegloticase considered when initial treatments are ineffective. Addressing comorbid conditions like hypertension and diabetes can further improve treatment outcomes. For individuals with CRG, continuous management, patient education, and routine follow-ups are crucial. Collaboration with specialists, including rheumatologists and nephrologists, may be necessary to ensure comprehensive care and optimize long-term management.
Chronic Refractory Gout Market Outlook
Chronic Refractory Gout (CRG) is a severe form of gout characterized by persistent symptoms and frequent flare-ups despite standard treatments. Managing CRG is challenging and requires a combination of pharmacological and lifestyle interventions.
The primary goal is to lower serum urate levels and prevent flare-ups. First-line treatments include xanthine oxidase inhibitors like allopurinol and febuxostat, but these may be ineffective or poorly tolerated in some patients. Uricosuric agents such as probenecid can aid uric acid excretion, though their efficacy is limited in those with renal impairment. For refractory cases, biologic agents like pegloticase offer an alternative by converting uric acid into a more soluble form, but they come with risks such as infusion reactions and reduced efficacy over time.
Non-pharmacological strategies, including dietary modifications and weight management, play a crucial role in controlling CRG. Patients are advised to avoid purine-rich foods, alcohol, and fructose while increasing hydration and consuming dairy products to help lower urate levels.
Despite available treatments, CRG remains a complex condition with unmet needs. Ongoing research and the development of new therapies are essential to improving long-term outcomes for patients.
Chronic Refractory Gout Marketed Drugs
KRYSTEXXA (Pegloticase): Amgen
Chronic Refractory Gout Emerging Drugs
SEL-212: Cartesian Therapeutics/Swedish Orphan Biovitrum (Sobi)
AR882: Arthrosi Therapeutics
Chronic Refractory Gout Key Companies
Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others
For more information, visit Chronic Refractory Gout Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Chronic Refractory Gout Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Chronic Refractory Gout, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Chronic Refractory Gout epidemiology in the 7MM
Chronic Refractory Gout marketed and emerging therapies
Chronic Refractory Gout companies
Chronic Refractory Gout market drivers and barriers
Table of Contents:
1 Chronic Refractory Gout Market Key Comprehensive Insights
2 Chronic Refractory Gout Market Report Introduction
3 Competitive Intelligence Analysis for Chronic Refractory Gout
4 Chronic Refractory Gout Market Analysis Overview at a Glance
5 Executive Summary of Chronic Refractory Gout
6 Chronic Refractory Gout Epidemiology and Market Methodology
7 Chronic Refractory Gout Epidemiology and Patient Population
8 Chronic Refractory Gout Patient Journey
9 Chronic Refractory Gout Treatment Algorithm, Chronic Refractory Gout Current Treatment, and Medical Practices
10 Key Endpoints in Chronic Refractory Gout Clinical Trials
11 Chronic Refractory Gout Marketed Therapies
12 Chronic Refractory Gout Emerging Therapies
13 Chronic Refractory Gout: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Chronic Refractory Gout
16 Chronic Refractory Gout Market Key Opinion Leaders Reviews
18 Chronic Refractory Gout Market Drivers
19 Chronic Refractory Gout Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Chronic Refractory Gout Epidemiology 2034
DelveInsight’s “Chronic Refractory Gout – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Chronic Refractory Gout epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Refractory Gout Pipeline 2024
“Chronic Refractory Gout Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Refractory Gout market. A detailed picture of the Chronic Refractory Gout pipeline landscape is provided, which includes the disease overview and Chronic Refractory Gout treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
